JournalArta
Monday, November 16, 2026 · JakartaS&P 7,561.67 ▼0.41%USD/IDR 18,268 ▲0.22%
JournalArta
Global Edition
beyond headlines
Advertisement

Bristol-Myers Squibb (BMY) Stock Rises 1.78% (November 13, 2026): Up 2.1% in Five Sessions

Technical analysis of BMY stock on November 13, 2026: price 63.43 USD, trend uptrend, RSI 55.9, support 58.83, resistance 64.19.

By Elena Vance
November 16, 20264 min read
Bristol-Myers Squibb (BMY) Stock Rises 1.78% (November 13, 2026): Up 2.1% in Five Sessions
Logo Bristol-Myers Squibb — JournalArta illustration

Why BMY is in focus today

    Selected automatically from 8 NYSE (US) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.

    Bristol-Myers Squibb shares rose 1.78% to $63.43 on the New York Stock Exchange on Friday, November 13, as a same-session golden cross and positive momentum signals put the drugmaker’s shares near the top of their recent range. The move extended gains to 2.08% over five sessions and 6.16% over one month, while trading volume remained below its 20-day average.

    Trend & Price Action

    The share price closed above both the 20-day simple moving average (SMA20), at $62.08, and the 50-day average, at $61.90. The SMA20 rose 1.62% over five days, and its same-session move above the SMA50 formed a golden cross, a signal that shorter-term price direction has strengthened relative to the medium-term trend. The combination supports the uptrend, though a moving-average cross is a lagging measure and does not by itself guarantee further gains. BMY stands at 86% of its 20-session range, between support at $58.83 and resistance at $64.19. It is also approaching the upper Bollinger band at $64.35; the band’s 7.3% width is narrowing, a squeeze that can precede a larger move but does not indicate its direction.
    Price action chart of BMY
    3-month price action chart of BMY: price, SMA20/50, Bollinger, support & resistance.
    Advertisement

    Oscillators & Momentum

    Momentum readings are positive but not stretched. The RSI is 55.9, in neutral territory, while Stochastic %K at 61.9 and %D at 52.1 are also neutral. Those readings suggest the recent advance has not yet pushed the shares into technically overbought territory. The MACD is above its signal line, with a positive histogram, pointing to positive momentum consistent with the uptrend. The indicators therefore broadly confirm the price structure, while leaving room for the share price to meet resistance near the upper band.
    Momentum chart of BMY
    Momentum chart of BMY: RSI(14), MACD, Stochastic.

    Volatility & Volume

    The average true range (ATR), a measure of typical price movement, is $1.72, or 2.7% of the share price, indicating moderate volatility. That makes a breakout from the narrowing Bollinger bands plausible, but it also means ordinary daily swings could test nearby levels. Friday’s volume was 9,273,900 shares, about 0.9 times the 20-day average of 10,115,415. Participation was therefore lighter than usual despite the price gain. On-balance volume (OBV), which tracks whether volume tends to accompany rising or falling prices, is rising and offers a supportive signal, though the below-average session volume tempers the confirmation.
    Advertisement

    Key Levels & Scenarios

    A sustained move through resistance at $64.19 and the upper Bollinger band at $64.35 would strengthen the case that the squeeze is resolving upward. Failure to clear that area could leave BMY consolidating above its moving averages; a drop below the SMA20 at $62.08 would weaken the near-term setup, while the 20-session support at $58.83 marks a deeper reference point. The three-month high is $68.64 and the low is $56.15.

    Fundamental Context

    According to its SEC filing, Bristol-Myers Squibb reported revenue of $13.07 billion for the quarter ended September 30, 2026, up 6.9% from $12.22 billion a year earlier. Net income was $2.16 billion, compared with $2.20 billion in the year-earlier quarter, and diluted earnings per share were $1.05. The revenue increase alongside slightly lower net income shows that sales growth did not translate into higher profit for the period.
    Advertisement

    Technical Verdict: BUY

    The JournalArta Research verdict is BUY, based on a +92 score, with three bullish technical signals and no bearish signals. The case rests on the same-session golden cross, the price holding above its 50-day average, and rising OBV confirming the uptrend. The RSI at 55.9 remains neutral, while below-average volume is a caution on the strength of participation. The verdict is invalidated if the price falls below the specified stop loss of $60.50. - Entry range: $62.15–$63.43 - Exit targets: $67.82 (target 1) and $72.22 (target 2) - Stop-loss protection: $60.50 - Valid until: December 12, 2026 In plain English, the technical signals currently favor further gains, but a fall below $60.50 would break the setup.
    Advertisement

    Summary Data BMY

    Last price63.43 USD
    Change 1 day / 5 days / 1 month1.78% / 2.08% / 6.16%
    Trend / MA-crossuptrend / golden
    SMA20 / SMA5062.08 / 61.90
    RSI (14) / Stochastic %K55.9 / 61.9
    Bollinger %B / ATR80% / 1.72
    Support / Resistance 20 days58.83 / 64.19
    Data as of14 November 2026 04:00 WIB
    JournalArta research verdict (score)Buy (+92)
    Entry zone62.15 – 63.43
    Target 1 / 267.82 / 72.22
    Stop loss60.50
    Reward/risk1.5 / 3.0

    Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.

    Advertisement
    Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
    Advertisement
    Most Read
    1. 1I’m A Celebrity 2026 Line-Up: Rooney Leads 11 Stars Into Jungle
    2. 2Mavericks Surfers Race to California for Waves Near 50 Feet
    3. 3NYC Medical Examiner Has Not Determined Cause of Death of Beau Rose Jessup
    4. 4Mountaineer Finds Ice Age Cave Bear Graveyard in the Dolomites
    5. 5Rugby League World Cup Final 2026: Kick-Off Times and How to Watch Kangaroos v New Zealand
    Advertisement
    Don't Miss

    Latest News

    All stories →
    1. Markets · FintechProject Meridian FX APAC Tests Settlement Across Three SystemsNov 16
    2. Technology · Apps & SoftwareSalesforce, HubSpot and Zoho CRM Pricing for Growing TeamsNov 16
    3. World · Americas & AfricaMark Carney Says Canada Could Turn to Chinese AutomakersNov 16
    4. Markets · Stocks10 Indian Stocks Surged 123% on Airbus, Boeing OrdersNov 16
    5. Advertisement
    6. Lifestyle · EntertainmentMidnight Diner Netflix Just Released Returns After Seven YearsNov 16
    7. Markets · StocksMicron Stock Falls 28% as $35.16 Billion Buyback NearsNov 16
    8. Technology · Apps & SoftwareAWS, Azure and Google Cloud Egress Fees: What Buyers PayNov 16
    9. Markets · StocksDow Jones Futures Fall as Nvidia Earnings and Anthropic IPO NearNov 16